The Value of Excipients and the Required Understanding of the Biological System in Product Development: An Impactful Example of Curaderm, a Topical Skin Cancer Treatment
The incidences of nonmelanoma skin cancer are increasing worldwide, and the ongoing war on its treatment necessitates the development of effective and non-invasive methods. Through basic and clinical research, non-invasive treatments like Curaderm have been developed, leading to improved quality of life for patients. Excipients, previously considered inactive ingredients, play a crucial role in enhancing the performance of topical formulations. The development of Curaderm emphasizes the importance of understanding the interactions between active ingredients, excipients, and the biological system to create effective and affordable pharmaceutical formulations. The systematic approach taken in the development of Curaderm, starting from the observation of the anticancer activity of natural solasodine glycosides and progressing through toxicological and efficacy studies in cell culture, animals, and humans, has provided insights into the pharmacokinetics and pharmacodynamics of solasodine glycosides. It is crucial to determine these pharmacological parameters within the skin’s biological system for maximal effectiveness and cost-effectiveness of a skin cancer treatment. Curaderm, as a topical treatment for nonmelanoma skin cancer, offers benefits beyond those obtained from other topical treatments, providing hope for improved quality of life for patients.
References
[1]
Cham, B.E. and Wilson, L. (1987) HPLC of Glycoalkaloids from Solanum sodomaeum. Planta Medica, 1, 59-62. https://doi.org/10.1055/s-2006-962621
[2]
Cham, B.E. (1988) Monograph BEC. Drugs of the Future, 13, 714-716. https://doi.org/10.1358/dof.1988.013.08.63026
Cham, B.E. (2013) Inspired by Nature, Proven by Science. The New Generation Cancer Treatment That Causes Cancer Cells to Commit Suicide. 1st Edition, Colorite Graphics, Port Vila, 264 p.
[5]
Cham, B.E. (2017) Solasodine, Solamargine and Mixtures of Solasodine Rhamnosides: Pathway to Expansive Clinical Anticancer Therapies. International Journal Clinical Medicine, 8, 692-713. https://doi.org/10.4236/ijcm.2017.812064
[6]
Millward, M., Powell, A., Tyson, S., Daly, P., Ferguson, R. and Carter, S. (2005) Phase 1 Trial of Coramsine (SBP002) in Patient with Advanced Solid Tumors. Journal Clinical Oncology, 23, 3105. https://doi.org/10.1200/jco.2005.23.16_suppl.3105
[7]
Chase, T., Cham, K.E. and Cham, B.E. (2020) Evaluation of Dermal Irritation and Skin Sensitization by Curaderm. International Journal of Clinical Medicine, 11, 548-558. https://doi.org/10.4236/ijcm.2020.119047
[8]
Daunter, B. and Cham, B.E. (1990) Solasodine Glycosides. In Vitro Preferential Cytotoxicity for Human Cancer Cells. Cancer Letters, 55, 209-220. https://doi.org/10.1016/0304-3835(90)90121-D
[9]
Cham, B.E., Gilliver, M. and Wilson, L. (1987) Antitumour Effects of Glycoalkaloids Isolated from Solanum sodomaeum. Planta Medica, 1, 34-36. https://doi.org/10.1055/s-2006-962612
[10]
Cham, B.E. and Meares, H.M. (1987) Glycoalkaloids from Solanum sodomaeum L. Are Effective in the Treatment of Skin Cancers in Man. Cancer Letters, 36, 111-118. https://doi.org/10.1016/0304-3835(87)90081-4
[11]
Cham, B.E., Daunter, B. and Evans, R. (1991) Topical Treatment of Malignant and Premalignant Skin Cancers by Very Low Concentrations of a Standard Mixture of Solasodine Glycosides. Cancer Letters, 59, 183-192. https://doi.org/10.1016/0304-3835(91)90140-D
[12]
Punjabi, S., Cook, I., Kersey, P., Marks, R., Finlay, A., Sharpe, G. and Cerio, R. (2000) A Double Blind, Multi-Centre Parallel Group Study of BEC-5 Cream in Basal Cell Carcinoma. European Academy Dermatology Venereology, 14, 47-60.
[13]
Cham, B.E. (2014) A Review of Solasodine Rhamnosides Therapy for In-Situ Squamous Cell Carcinoma on the Penis. British Journal of Medicine and Medical Research, 4, 621-631. https://doi.org/10.9734/BJMMR/2014/4677
[14]
Goldberg, L.H., Landau, J.M., Moody, M.N. and Vergilis-Kalner, I.J. (2011) Treatment of Bowen’s Disease on the Penis with Low Concentrations of a Standard Mixture of Solasodine Glycosides and Liquid Nitrogen. Dermatologic Surgery, 37, 858-861. https://doi.org/10.1111/j.1524-4725.2011.02014.x
[15]
Lipscombe, R., Carter, S. and Ruane, M. (2005) Rhamnose Binding Protein. US Patent No. 6930171.
[16]
Cham, B.E. (2007) Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers. Research Journal Biological Sciences, 2, 503-514.
[17]
Wang, Y., Gao. J., Gu, G., Li, G., Cui, C., Sun, B. and Long, H. (2007) In Situ Receptor Visualisation and Its Mediated Anticancer Activity for Solasodine Rhamnosides. ChemBioChem, 12, 2418-2420. https://doi.org/10.1002/cbic.201100551
[18]
An, W., Lai, H., Zhang, Y., Liu, M., Lin, X. and Cao, S. (2019) Apoptotic Pathway as the Therapeutic Target for Anticancer Traditional Chinese Medicines. Frontiers in Pharmacology, 10, Article 758. https://doi.org/10.3389/fphar.2019.00758
[19]
Li, X., Zhao, Y., Wu, W.K., Liu, S., Cui, M. and Lou, H. (2011) Solamargine Induces Apoptosis with p53 Transcription-Dependent and Transcription-Independent Pathways in Human Osteosarcoma U2OS Cells. Life Sciences, 88, 314-321. https://doi.org/10.1016/j.lfs.2010.12.006
[20]
Al Sinani, S.S., Eltayeb, E.A., Coomber, B.L. and Adham, S.A. (2016) Solamargine Triggers Cellular Necrosis Selectively in Different Types of Human Melanoma Cancer Cells through Extrinsic Lysosomal Mitochondrial Death Pathways. Cancer Cell International, 16, 287-294. https://doi.org/10.1186/s12935-016-0287-4
[21]
Zang, X., Yan, Z., Xu, T., An, Z., Chen, W., Wang, X., Huang, M. and Zhu, F. (2018) SM Derived from Solanum nigrum Induces Apoptosis of Human Cholangio Carcinoma QBC939 Cells. Oncology Letters, 15, 6329-6335. https://doi.org/10.3892/ol.2018.8171
[22]
Al Sinani, S.S.S. and Eltayeb, E.A. (2017) The Steroidal Glycoalkaloids Solamargine and Solasonine in Solanum Plants. South Africa Journal Botany, 112, 253-269. https://doi.org/10.1016/j.sajb.2017.06.002
[23]
Kalalinia, F. and Korimi-Sani, I. (2017) Anticancer Properties of Solamargine: A Systematic Review. Phytotherapy Research, 31, 858-870. https://doi.org/10.1002/ptr.5809
[24]
Sani, I.K., Marashi, S.H. and Kalalinia, F. (2015) Solamargine Inhibits Migration and Invasion of Human Hepatocellular Carcinoma Cells through Down-Regulation of Matrix Metalloproteinases 2 and 9 Expression and Activity. Toxicology in Vitro, 29, 893-900. https://doi.org/10.1016/j.tiv.2015.03.012
[25]
Li, X., Zhao, Y., Liu, S., Cui, M. and Lou, H. (2011) Induction of Actin Disruption and Downregulation of P-Glycoprotein Expression of Solamargine in Multidrug-Resistant K562/A02 Cells. Clinical Medicine Journal, 124, 2038-2044. https://doi.org/10.3892/ol.2011.500
[26]
Chase, T.R., Cham, K.E. and Cham, B.E. (2020) Curaderm, the Long-Awaited Breakthrough for Basal Cell Carcinoma. International Journal of Clinical Medicine, 11, 59-604. https://doi.org/10.4236/ijcm.2020.1110050
[27]
Cham, B.E. (2022) The Pharmacology of Curaderm in the Treatment of Basal Cell Carcinoma. Clinical Medical Review and Case Reports, 9, Article 399. https://doi.org/10.23937/2378-3656/1410399
[28]
Chang, L.C., Tsai, T.R., Wang, J.J., Lin, C.N. and Kuo, K.W. (1998) The Rhamnose Moiety of Solamargine Plays a Crucial Role in Triggering Cell Death by Apoptosis. Biochemical and Biophysical Research Communications, 242, 21-25. https://doi.org/10.1006/bbrc.1997.7903
[29]
Cham, B.E. (2020) Combination Treatment with BEC and Cisplatin Synergistically Augments Anticancer Activity and Results in Increased Absolute Survival. Journal of Cancer Therapy, 11, 470-482. https://doi.org/10.4236/jct.2020.118040
[30]
Cham, B.E. and Daunter, B. (1990) Solasodine Glycosides. Selective Cytotoxicity for Cancer Cells and Inhibition of Cytotoxicity by Rhamnose in Mice with Sarcoma 180. Cancer Letters, 55, 221-225. https://doi.org/10.1016/0304-3835(90)90122-E
[31]
Cham, B.E., Chase, T.R. and Cham, K.E. (2017) Glycoalkaloid Combinations and Various Uses Thereof. Patent No. WO2017147659A1.
[32]
Cham, A., Cham, K., Chase, T. and Cham, B.E. (2015) A Standardized Plant Extract Containing a Target Compound Is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5. Journal Cancer Treatment Research, 3, 22-27. https://doi.org/10.11648/j.jctr.20150302.12
[33]
Cham, B.E. (1994) Solasodine Glycosides as Anticancer Agents: Preclinical and Clinical Studies. Asia Pacific Journal Pharmacology, 9, 113-118.
[34]
Cham, B.E. and Chase, T.R. (2012) Solasodine Rhamnosyl Glycosides Cause Apoptosis in Cancer Cells. Do They Also Prime the Immune System Resulting in Long-Term Protection Against Cancer? Planta Medica, 78, 349-353. https://doi.org/10.1055/s-0031-1298149
[35]
Cham, B.E. (2021) The Evolution of Curaderm from the Eggplant Which Led to the Revolution of Skin Cancer Treatment. https://www.amazon.com/evolution-curaderm-eggplant-revolution-treatment-ebook/dp/b09mvp5m3l/ref=sr_1_1?keywords=the+evolution+of+curaderm&qid=1639040738&sr=8-1
[36]
Cham, B.E. (2007) Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers. Research Journal Biological Sciences, 2, 503-5142.
[37]
Cham, B.E. (2013) Drug Therapy: Solamargine and Other Solasodine Rhamnosyl Glycosides as Anticancer Agents. Modern Chemotherapy, 2, 33-49. https://doi.org/10.4236/mc.2013.22005
[38]
Cham, B.E. (2008) Cancer Intralesion Chemotherapy with Solasodine Rhamnosyl Glycosides. Research Journal Biological Sciences, 3, 1008-1017.
[39]
Punjabi, S., Cook, L.J., Kersey, P., Marks, R. and Cerio, R. (2008) Solasodine Glycoalkaloids: A Novel Topical Therapy for Basal Cell Carcinoma. A Double Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study. International Journal Dermatology, 47, 78-82. https://doi.org/10.1111/j.1365-4632.2007.03363.x
[40]
Cerio, R. and Punjabi, S. (2002) Clinical Appraisal of BEC5. Dermatology Department, Barts and the London NHS.
[41]
Tambuscio, A., Siliprandi, L., Dario, M., Cham, A., Cham, B. and Bordignon, M. (2016) Treatment of Cutaneous Carcinomas with a Topical Cream Containing Solasodine Rhamnosides: Focus on Efficacy, Compliance and Cosmetic Outcomes. European Academy of Dermatology and Venereology Congress, Athens, 19-21 May 2016, 248 p.
[42]
Cham, B.E. (2007) The Eggplant Cancer Cure: A Treatment for Skin Cancers and New Hope for Other Cancers from Nature’s Pharmacy. Smart Publications, Port Vila.
[43]
Cham, B.E. (2007) Solasodine Rhamnosyl Glycosides in a Cream Formulation Is Effective for Treating Large and Troublesome Skin Cancers. Research Journal of Biological Sciences, 2, 749-761.
[44]
Cham, B.E. (2009) When Does Alternative Become Orthodox? Skin Cancer Treatment with Solasodine Rhamnosyl Glycosides in Its Transitional Stage, a Case Study. Evidence-Based Complement Alternative Medicine, 6, 415-420.
[45]
Cham, B.E. (2011) Topical Solasodine Rhamnosyl Glycosides Derived from the Eggplant Treats Large Skin Cancers: Two Case Reports. International Journal Clinical Medicine, 2, 473-477. https://doi.org/10.4236/ijcm.2011.24080
[46]
Chase, T.R. (2011) Curaderm BEC5 for Skin Cancers, Is It? An Overview. Journal Cancer Therapy, 2, 728-745. https://doi.org/10.4236/jct.2011.25099
[47]
Cham, B.E. (2012) Intralesion and CuradermBEC Topical Combination Therapies of Solasodine Rhamnosyl Glycosides Derived from the Eggplant or Devil’s Apple Result in Rapid Removal of Large Skin Cancers. Methods of Treatment Compared. International Journal Clinical Medicine, 3, 115-124. https://doi.org/10.4236/ijcm.2012.32024
[48]
Cham, B.E. (2013) Topical CuradermBEC5 Therapy for Periocular Nonmelanoma Skin Cancer: A Review of Clinical Outcomes. International Journal Clinical Medicine, 4, 233-238. https://doi.org/10.4236/ijcm.2013.45041
[49]
Cham, A. and Cham, B.E. (2015) Treatment of Skin Cancer with a Selective Apoptotic-Inducing CuradermBEC5 Topical Cream Containing Solasodine Rhamnosides. International Journal Clinical Medicine, 6, 326-333. https://doi.org/10.4236/ijcm.2015.65042
[50]
Cham, B.E., Cham, K., Cham, A., Chase, T. and Zhou, V. (2015) Treatment of Non Melanoma Skin Cancers: An Intra-Comparison Study of CuradermBEC5 and Various Established Modalities. Journal Cancer Therapy, 6, 1045-1053. https://doi.org/10.4236/jct.2015.612114
[51]
Cham, B.E. (2013) Solasodine Glycosides: A Topical Therapy for Actinic Keratosis. A Single-Blind, Randomized, Placebo-Controlled, Parallel Group Study with Curaderm. Journal of Cancer Therapy, 4, 588-596. https://doi.org/10.4236/jct.2013.42076
[52]
Bordingnon, M. (2016) Efficacy and Safety of CuradermBEC5 in the Treatment of Basal Cell Carcinoma: A Pilot Study in the Italian Population. European Academy Dermatology Venereology Congress, Athens, 19-21 May 2016, 249 p.
[53]
Dobrokhotova, F.Z., Betsev, A.F. and Belysheva, T.S. (2016) The Use of Kuraderm Drug in the Treatment of Basal Cell Carcinoma of the Head and Neck. Head and Neck Tumors, 6, 22-26. https://doi.org/10.17650/2222-1468-2016-6-3-22-26
[54]
Batsev, A.F., Dobrokhotova, V.Z. and Cham, B.E. (2016) Topical Cream CuradermBEC5 Treats a Recalcitrant Basal Cell Carcinoma. Clinical Medical Reviews and Case Reports, 3, Article 098. https://doi.org/10.23937/2378-3656/1410098
[55]
Cham, B.E. (2020) First in Man Topical Treatment of Melanoma with Solasodine Glycosides in a Formulation Curaderm. Journal of Cancer Therapy, 11, 617-630. https://doi.org/10.4236/jct.2020.1110052
[56]
Cham, B.E. (2015) CuradermBEC5, Natural Non-Invasive Medication for Skin Cancer, Biopsy and 5 Year Cancer-Free Criteria. 2nd Edition, Curaderm Global Ltd., Vanuatu.
[57]
Gupta, N., Gupta, G.D. and Singh, D. (2022) Localized Topical Drug Delivery Systems for Skin Cancer: Current Approaches and Future Prospects. Frontier Nanotechnology, 4, Article 1006628. https://doi.org/10.3389/fnano.2022.1006628
[58]
Inam, S.S. (2023) Topical Formulation Constituted with Transferosomes for the Treatment of Non-Melanoma Skin Cancer. Asian Journal of Pharmaceutical and Clinical Research, 16, 27-32. https://doi.org/10.22159/ajpcr.2023.v16i5.47033
[59]
Kao, S.Z., Ekwueme, D.U., Holman, D.M., Rim, S.H., Thomas, C.C. and Saraiya, M. (2023) Economic Burden of Skin Cancer Treatment in the USA: An Analysis of the Medical Expenditure Panel Survey Data 2012-2018. Cancer Causes & Controls, 34, 205-212. https://doi.org/10.1007/s10552-022-01644-0
[60]
Cham, B.E. (2023) Holistic Approach in the Treatment of Actinic Keratosis: Benefits and Disadvantages of 5-Fluorouracil, Imiquimod, Diclofenac and Curaderm. International Journal Clinical Medicine, 14, 319-331. https://doi.org/10.4236/ijcm.2023.147027
[61]
Cham, B.E. (2024) Gold Standard for Skin Cancer Treatment: Surgery or Micrographic Molecular-Cellular Therapy?
